Today on The Fundamentals is Dr. Maria Castro, the R.C. Schneider collegiate professor of neurosurgery, and a professor of cell and developmental biology at the University of Michigan Medical School. Her research program aims to develop immunotherapies for primary and metastatic brain cancer, studying basic immune biology mechanisms leading to clinical implementation. She has been inducted into the American Association for the Advancement of Sciences, the Latin American Academy of Sciences, and the American Institute for Medical and Biological Engineering College of Fellows. She has won numerous awards for her contributions to basic science and cancer research and is a diversity ambassador for the Cancer Biology Graduate Training Program. You can learn more about Dr. Castro here, and you can follow her @castro2355_mg, the Rogel Cancer Center @UMRogelCancer, the department of neurosurgery @umichneuro, Michigan Neurscience Institute @UM_MNI and the department of cell and developmental biology @UMCDB on X

A survey focused on how much people in their teens and early 20s know about periods and their experience and attitudes around “period poverty”.

Four faculty and two staff members from the departments of Anesthesiology, Neurology, Radiology and Surgery, and the Office of Graduate Medical Education (GME), are recipients of GME Awards for 2024

Survey shows many teens and young adults support making menstrual products more accessible to fight "period poverty."

Many women don’t get cervical cancer screening such as Pap tests, or don’t go for follow up diagnostic tests; a new study shows what could happen if all of them did.

Patients can now enroll in a clinical trial to test a groundbreaking nonsurgical treatment for cervical lesions that affect nearly 300,000 women in the United States every year.

Lung disease specialist comes to Michigan from Vanderbilt University School of Medicine to lead largest department

Elective surgery study shows older adults have concerns about what it will cost them, how much work they’ll miss and whether they’ll catch COVID-19.

Research from Michigan Medicine experts is shedding light and potentially expanding options for patients living with an aggressive childhood cancer.

Recently approved by the Food and Drug Administration, Pluvicto is a radionuclide-labelled drug administered to patients showing promising results.

Findings from researchers at the University of Michigan Health Rogel Cancer Center, published in Cancer Discovery, show how a specific nucleotide metabolite called GTP controls responses to radiation and chemotherapy in an unexpected way.

Technology developed at U-M uses sound waves to destroy tissue, providing a new type of cancer therapy

Michigan Medicine has developed a new technique that provides a non-invasive alternative to surgery, chemotherapy and radiation treatments for cancer.

Adults, especially people over 50, should get immunized against COVID-19, flu and other infections, to prevent fall and winter illness, hospitalization and worse